Advanced Accelerator Applications Revenue and Competitors

Claim your profile

Location

$144.3M

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • Advanced Accelerator Applications's estimated annual revenue is currently $194.4M per year.(i)
  • Advanced Accelerator Applications's estimated revenue per employee is $201,000
  • Advanced Accelerator Applications's total funding is $144.3M.

Employee Data

  • Advanced Accelerator Applications has 967 Employees.(i)
  • Advanced Accelerator Applications grew their employee count by 14% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$354.3M553-9%$567.1MN/A
#2
$405.8M2019-1%N/AN/A
#3
$33.8M168-1%N/AN/A
#4
$21.1M105-5%N/AN/A
#5
$1183.5M58883%N/AN/A
#6
$11.1M55-4%$9.8MN/A
#7
$5.8M290%N/AN/A
#8
$20.7M103N/AN/AN/A
#9
$36.2M180-6%N/AN/A
#10
$1.4M7-30%N/AN/A

Advanced Accelerator Applications (AAA) is an innovative radiopharmaceutical company that develops, produces and commercializes molecular nuclear medicine, or MNM, products. AAA is a European leader in the production and commercialization of molecular nuclear diagnostic radiopharmaceuticals for PET and SPECT. These radiopharmaceuticals are mainly used for diagnosis in clinical oncology, cardiology and neurology. AAA’s lead therapeutic product candidate, Lutathera, is a novel MNM compound under development for the treatment of midgut neuroendocrine tumors, or NETs, a significant unmet medical need. Lutathera is a Lutetium-177, or Lu-177, labeled somatostatin analogue peptide that has received orphan drug designation from the European Medicines Agency, or EMA, and the U.S. Food and Drug Administration, or FDA. Orphan drug designation is a special status conferred by the FDA and EMA to a product candidate that treats a rare disease or condition, and the designation entitles the product candidate’s sponsor to various development incentives. Lutathera was also granted Fast-Track designation by the FDA in April 2015 for the treatment of inoperable progressive midgut NETs. In a pivotal Phase 3 trial for the treatment of inoperable progressive midgut NETs, Lutathera has produced favorable initial results compared to the current standard of care, treatment with Octreotide LAR alone

keywords:N/A

$144.3M

Total Funding

967

Number of Employees

$194.4M

Revenue (est)

14%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Advanced Accelerator Applications News

2022-04-20 - Evolving Role of Prostate-Specific Membrane Antigen ...

Consulting or Advisory Role: Bayer, Endocyte, Advanced Accelerator Applications, ORIC Pharmaceuticals, Johnson & Johnson, Curium Pharma,...

2022-04-19 - Paraganglioma Treatment Market, Future Trend Scenario ...

... Inc, AstraZeneca, Advanced Accelerator Applications ... category market growths, application niches and dominance, product approvals,...

2022-03-22 - Novartis Pluvicto™ approved by FDA as first targeted ...

Advanced Accelerator Applications (AAA), a Novartis company, specializes in targeted radioligand therapies and precision imaging radioligands...

2014-02-17 - Advanced Accelerator Applications Raises €41M in Funding

Advanced Accelerator Applications, a Saint Genis Pouilly, France-based specialist in Molecular Nuclear Medicine (MNM), raised €41m in funding. The round was led by biotech and pharma investment company HBM Healthcare Investments Ltd (€20m), with participation from existing and new shareholders, ...

2011-07-29 - Advanced Accelerator Applications Completes €40M Capital Increase

Advanced Accelerator Applications (AAA), a European developer of diagnostic and therapeutic applications and products, has completed a €40m capital increase. The fundraising was subscribed by existing and new shareholders, including private investors and pharmaceutical companies. New shareholde ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$307.9M9691%N/A
#2
$299.1M971-8%N/A
#3
$139.9M980-2%N/A
#4
$346.5M9859%$750M
#5
$248.5M986N/AN/A